Future work is needed to clarify how NASH increases the risk of HCC following anti-PD-1/PDL-1 therapy and the mechanisms by which activated CXCR6+ CD8 T cells promote carcinogenesis. The gene discussed is CXCR6; the disease is metabolic dysfunction-associated steatohepatitis.